CIA BRASILEIRA DE DIS- ADR (CBD) Stock Fundamental Analysis

NYSE:CBD • US20440T3005

0.445 USD
-0.01 (-3.05%)
At close: Apr 18, 2024
0.4357 USD
-0.01 (-2.09%)
After Hours: 4/18/2024, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

CBD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 38 industry peers in the Consumer Staples Distribution & Retail industry. Both the profitability and financial health of CBD have multiple concerns. CBD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year CBD has reported negative net income.
  • In the past year CBD had a positive cash flow from operations.
  • In multiple years CBD reported negative net income over the last 5 years.
  • Of the past 5 years CBD 4 years had a positive operating cash flow.
CBD Yearly Net Income VS EBIT VS OCF VS FCFCBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 2B -2B 4B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -10.30%, CBD is doing worse than 78.05% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -48.12%, CBD is doing worse than 80.49% of the companies in the same industry.
  • The Return On Invested Capital of CBD (0.48%) is worse than 70.73% of its industry peers.
Industry RankSector Rank
ROA -10.3%
ROE -48.12%
ROIC 0.48%
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
CBD Yearly ROA, ROE, ROICCBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40

1.3 Margins

  • CBD has a worse Operating Margin (0.50%) than 68.29% of its industry peers.
  • CBD's Operating Margin has declined in the last couple of years.
  • CBD's Gross Margin of 25.02% is fine compared to the rest of the industry. CBD outperforms 63.41% of its industry peers.
  • CBD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.5%
PM (TTM) N/A
GM 25.02%
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
CBD Yearly Profit, Operating, Gross MarginsCBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CBD is destroying value.
  • The number of shares outstanding for CBD remains at a similar level compared to 1 year ago.
  • The debt/assets ratio for CBD is higher compared to a year ago.
CBD Yearly Shares OutstandingCBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M
CBD Yearly Total Debt VS Total AssetsCBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20B 40B 60B

2.2 Solvency

  • CBD has an Altman-Z score of 1.07. This is a bad value and indicates that CBD is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.07, CBD is doing worse than 73.17% of the companies in the same industry.
  • CBD has a Debt/Equity ratio of 1.72. This is a high value indicating a heavy dependency on external financing.
  • CBD has a worse Debt to Equity ratio (1.72) than 82.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.72
Debt/FCF N/A
Altman-Z 1.07
ROIC/WACC0.09
WACC5.48%
CBD Yearly LT Debt VS Equity VS FCFCBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 1.21 indicates that CBD should not have too much problems paying its short term obligations.
  • CBD has a Current ratio of 1.21. This is comparable to the rest of the industry: CBD outperforms 51.22% of its industry peers.
  • A Quick Ratio of 0.89 indicates that CBD may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.89, CBD is in the better half of the industry, outperforming 70.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 0.89
CBD Yearly Current Assets VS Current LiabilitesCBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • CBD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1171.43%.
  • CBD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.86%.
  • CBD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -17.17% yearly.
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%

3.2 Future

  • Based on estimates for the next years, CBD will show a very strong growth in Earnings Per Share. The EPS will grow by 24.83% on average per year.
  • The Revenue is expected to grow by 8.97% on average over the next years. This is quite good.
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CBD Yearly Revenue VS EstimatesCBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20B 40B 60B 80B
CBD Yearly EPS VS EstimatesCBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CBD. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBD Price Earnings VS Forward Price EarningsCBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CBD is valued cheaper than 85.37% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5
CBD Per share dataCBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CBD's earnings are expected to grow with 24.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.43%
EPS Next 3Y24.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. Dividend

5.1 Amount

  • CBD has a Yearly Dividend Yield of 13.41%, which is a nice return.
  • The stock price of CBD dropped by -47.63% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • Compared to an average industry Dividend Yield of 0.69, CBD pays a better dividend. On top of this CBD pays more dividend than 100.00% of the companies listed in the same industry.
  • CBD's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 13.41%

5.2 History

  • The dividend of CBD decreases each year by -24.04%.
  • CBD has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-24.04%
Div Incr Years0
Div Non Decr Years0
CBD Yearly Dividends per shareCBD Yearly Dividends per shareYearly Dividends per share 2016 2018 2019 2020 2021 2022 0.5 1 1.5 2

5.3 Sustainability

  • The earnings of CBD are negative and hence is the payout ratio. CBD will probably not be able to sustain this dividend level.
DP-4.93%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
CBD Yearly Income VS Free CF VS DividendCBD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 0 1B -1B 2B -2B

More info and screens

Find the best dividend stocksShow peers with best dividend

CIA BRASILEIRA DE DIS- ADR

NYSE:CBD (4/18/2024, 8:04:00 PM)

After market: 0.4357 -0.01 (-2.09%)

0.445

-0.01 (-3.05%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)02-21
Earnings (Next)05-01
Inst Owners0.12%
Inst Owner Change-2.09%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap218.06M
Revenue(TTM)19.25B
Net Income(TTM)-2.27B
Analysts50
Price Target1.53 (243.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 13.41%
Yearly Dividend0.41
Dividend Growth(5Y)-24.04%
DP-4.93%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-273.86%
Min EPS beat(2)-455.83%
Max EPS beat(2)-91.89%
EPS beat(4)0
Avg EPS beat(4)-228.76%
Min EPS beat(4)-455.83%
Max EPS beat(4)-25.58%
EPS beat(8)0
Avg EPS beat(8)-362.44%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.9%
Min Revenue beat(2)-4.34%
Max Revenue beat(2)-3.47%
Revenue beat(4)0
Avg Revenue beat(4)-27.12%
Min Revenue beat(4)-59.79%
Max Revenue beat(4)-3.47%
Revenue beat(8)2
Avg Revenue beat(8)-9.38%
Revenue beat(12)3
Avg Revenue beat(12)-9.97%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-19.66%
PT rev (3m)-10.73%
EPS NQ rev (1m)54.81%
EPS NQ rev (3m)58.85%
EPS NY rev (1m)49.53%
EPS NY rev (3m)46.14%
Revenue NQ rev (1m)-0.72%
Revenue NQ rev (3m)-1.13%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)-1.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.06
P/FCF N/A
P/OCF 1.99
P/B 0.24
P/tB 0.41
EV/EBITDA 5
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)0.22
OCFY50.28%
SpS7.65
BVpS1.88
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.3%
ROE -48.12%
ROCE 0.61%
ROIC 0.48%
ROICexc 0.63%
ROICexgc 0.76%
OM 0.5%
PM (TTM) N/A
GM 25.02%
FCFM N/A
ROA(3y)-3.02%
ROA(5y)-0.73%
ROE(3y)-14.58%
ROE(5y)-4.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-58.82%
ROICexgc growth 5Y-42.48%
ROICexc growth 3Y-57.55%
ROICexc growth 5Y-42.78%
OM growth 3Y-54.5%
OM growth 5Y-37.57%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.29%
GM growth 5Y1.26%
F-Score2
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 1.72
Debt/FCF N/A
Debt/EBITDA 6.59
Cap/Depr 103.08%
Cap/Sales 6.08%
Interest Coverage 250
Cash Conversion 45.66%
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 0.89
Altman-Z 1.07
F-Score2
WACC5.48%
ROIC/WACC0.09
Cap/Depr(3y)82.81%
Cap/Depr(5y)104.8%
Cap/Sales(3y)7.75%
Cap/Sales(5y)7.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1171.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.55%
EPS Next Y83.74%
EPS Next 2Y38.43%
EPS Next 3Y24.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-59.86%
Revenue growth 3Y-27.85%
Revenue growth 5Y-17.17%
Sales Q2Q%-69.65%
Revenue Next Year8.97%
Revenue Next 2Y6.92%
Revenue Next 3Y6.72%
Revenue Next 5Y8.97%
EBIT growth 1Y-87.1%
EBIT growth 3Y-67.17%
EBIT growth 5Y-48.29%
EBIT Next Year586.28%
EBIT Next 3Y102.85%
EBIT Next 5Y76.66%
FCF growth 1Y66.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y360.65%
OCF growth 3Y-50.85%
OCF growth 5Y-33.31%

CIA BRASILEIRA DE DIS- ADR / CBD FAQ

Can you provide the ChartMill fundamental rating for CIA BRASILEIRA DE DIS- ADR?

ChartMill assigns a fundamental rating of 2 / 10 to CBD.


What is the valuation status for CBD stock?

ChartMill assigns a valuation rating of 1 / 10 to CIA BRASILEIRA DE DIS- ADR (CBD). This can be considered as Overvalued.


Can you provide the profitability details for CIA BRASILEIRA DE DIS- ADR?

CIA BRASILEIRA DE DIS- ADR (CBD) has a profitability rating of 2 / 10.


Can you provide the financial health for CBD stock?

The financial health rating of CIA BRASILEIRA DE DIS- ADR (CBD) is 1 / 10.